Main Menu

Biosimilar Coding and Reimbursement under Medicare Part B

Christopher Stomberg, Ben Wolfert, Richard Manning
November 2017
Read the brief here

In this brief, Partners Christopher Stomberg and Richard Manning and Manager Ben Wolfert examine Medicare’s current reimbursement policy for biosimilar products, which are products the Food and Drug Administration has not approved as “interchangeable” with the reference biologic product. The study examines two existing Medicare Part B markets where circumstances similar to those that exist for biosimilars have progressed. The authors recommend two things: (i) the elimination of shared Average Sales Price (ASP) reimbursement and (ii) that biosimilar products be put on equal economic footing with both each other and the reference biologic by giving them a separate Healthcare Common Procedure Coding System and separate ASPs.

Jump to Page

We use cookies to optimize the performance of this site and give you the best user experience. By clicking "Accept," you agree to our use of cookies.

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.